Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael B. Osswald is active.

Publication


Featured researches published by Michael B. Osswald.


American Journal of Hematology | 2009

The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia

Bradley Alexander McGregor; Alexander W. Brown; Michael B. Osswald; Michael R. Savona

The standard dose of clofarabine is 52 mg/m2 for pediatrics and 40 mg/m2 in adults. Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo‐HSCT. All patients had a significant response to therapy. Published pharmacokinetic analysis revealed no difference in peak plasma or intracellular concentrations at clofarabine dosed above 40 mg/m2, yet inhibition of replication in leukemia cells was only sustained over 24 hr at 55 mg/m2. Despite this, there have been no reports of high dose clofarabine used in this setting. Our experience implies that there may be a niche role for clofarabine in reducing disease burden before allo‐HSCT for adults with relapsed ALL. Am. J. Hematol., 2009. Published 2009 Wiley‐Liss, Inc.


Journal of Oncology Practice | 2017

Implementing a Multidisciplinary Approach to Enhance Compliance With Guideline-Recommended Prechemotherapy Pneumococcal Vaccination in a Military-Based Medical Oncology Practice

Wilfred P. Delacruz; Sandra Terrazzino; Michael B. Osswald; Casey Payne; Brian Haney

PURPOSE Patients with cancer are at increased risk for invasive pneumococcal disease, including community-acquired pneumonia. Current Advisory Committee on Immunization Practices and National Cancer Comprehensive Network guidelines recommend pneumococcal vaccination for immunocompromised patients, including patients with cancer. METHODS We conducted a quality improvement (QI) project to enhance compliance with pneumococcal vaccination in patients before their chemotherapy. Baseline pneumococcal vaccination rates were gathered from July 2013 to June 2014. We reviewed the current guidelines for pneumococcal vaccinations in patients with cancer with physicians and encouraged them to prescribe the pneumococcal vaccination to patients before therapy. We also recruited our clinic nurse practitioner, who meets all patients for chemotherapy teaching, to prescribe the vaccine to patients younger than 65 years of age. RESULTS During the baseline period, of the 110 patients younger than 65 years who received chemotherapy, seven (6.4%) received the pneumococcal vaccine. Of the 90 patients (median age, 60 years; range, 20 to 86 years) who received chemotherapy during the study period, 58 were younger than 65 years, of whom three patients were already vaccinated before their diagnosis. Twenty-five (45.5%) patients were vaccinated through our QI project. We have improved our compliance with pneumococcal vaccination by 39% ( P < .001). CONCLUSION We have improved compliance with pneumococcal vaccination in patients with cancer receiving chemotherapy in our clinic through a QI project. We found that screening is best accomplished by a single person who is able to screen all patients. This practice is now a standard of care in our clinic.


Bone Marrow Transplantation | 2009

Pseudoaneurysm in the muscular artery of the right gluteal region following a BM harvest

Bradley Alexander McGregor; D W Ririe; Michael B. Osswald

BM harvesting is generally accepted as a safe procedure with minimal complications and is often performed as an ambulatory surgery. In addition to bleeding and infection, rarer complications have been reported to include air or fat embolism and fracture of the ilium.1, 2, 3 We report a patient who suffered a pseudoaneurysm of the muscular artery of the right gluteal region following BM harvest with massive blood loss.


International Journal of Artificial Organs | 2018

Salvage extracorporeal membrane oxygenation in induction-associated acute respiratory distress syndrome in acute leukemia patients: A case series

Nikhil Huprikar; Matthew R. Peterson; Jeffrey Dellavolpe; Valerie G. Sams; James H Lantry; Robert Walter; Michael B. Osswald; Kevin K. Chung; Phillip E Mason

Background: The prognosis of hematologic malignancies has improved over the past three decades. However, the prognosis in hematologic malignancies with severe acute respiratory distress syndrome has remained poor. Initial reports regarding the utility of extracorporeal membrane oxygenation in hematologic malignancies have been controversial, with limited evaluations of acute leukemia patients supported by extracorporeal membrane oxygenation. Methods: We conducted a retrospective review of patients with acute leukemia who developed acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support at our facility from July 2015 through August 2017. Results: Four cases of acute myelogenous leukemia with respiratory failure and acute respiratory distress syndrome treated with veno-venous extracorporeal membrane oxygenation while undergoing induction chemotherapy were identified. All patients completed induction therapy with addition of extracorporeal membrane oxygenation support, with two patients dying secondary to their acute leukemia and the other two surviving to allogeneic hematopoietic stem cell transplant. Overall, 75% (three of four) survived to decannulation with a 1-year survival rate following extracorporeal membrane oxygenation of 50% (two of four). Conclusion: Currently, the use of extracorporeal membrane oxygenation in patients with hematologic malignancies who develop severe acute respiratory distress syndrome remains controversial. Although extracorporeal membrane oxygenation in post-allogeneic hematopoietic stem cell transplant is associated with poorer outcomes, our data suggest that salvage extracorporeal membrane oxygenation support is a viable option to manage moderate to severe acute respiratory distress syndrome while completing therapeutic chemotherapy and following in the peri-induction phase of acute leukemia.


Military Medicine | 2016

Rates of Microbiologically Diagnosed Infection and Pathogen Detection in Hematopoietic Stem Cell Transplant Patients

Lauren E. Lee; Alice Barsoumian; Alexander W. Brown; Michael A. Wiggins; John S. Renshaw; Michael B. Osswald; Clinton K. Murray

ABSTRACT Infections remain a significant cause of mortality in hematopoietic stem cell transplant patients. Evaluations of causes of infection are often unrevealing, and at some sites, increasing rates of antimicrobial resistance have been noticed. We performed a retrospective analysis of infection rates and microbiologic testing yield, or percent of tests ordered to diagnose an infection, in the first 100 days of 30 allogeneic and 56 autologous stem cell transplants performed at San Antonio Military Medical Center from July 2011 to April 2014. Blood stream infections were diagnosed in 11.6% with a yield of 6%. Urinary tract infections were diagnosed in 2.3% with a yield of 3%. Clostridium difficile infections were diagnosed in 9.3% and testing yield was 6%. Incidence of respiratory viruses was 5.8% with 4 rhinoviruses/enteroviruses and 1 influenza virus identified. One Proteus mirabilis urinary isolate was an extended spectrum beta-lactamase producer. Five patients, 13% of allogeneic and 4% of autologous patients, died within the first 100 days post-transplantation. History of bacteremia was present in 60% of patients who died; however, only one died due to a microbiologically diagnosed infection. Improved diagnostic tests and methods are needed to increase yield of detection of infection in hematopoietic stem cell transplant patients.


Biology of Blood and Marrow Transplantation | 2018

Case Series of Extracorporeal Membrane Oxygenation during Acute Myelogenous Leukemia Induction

Matthew R. Peterson; Michael B. Osswald; Nikhil Huprikar


Journal of Thoracic Oncology | 2017

OA17.07 Time from the Identification of a Suspicious Pulmonary Lesion to the Treatment of Non-Small Cell Lung Cancer

Claire L. Hiles; Paul D. Hiles; Michael B. Osswald


Biology of Blood and Marrow Transplantation | 2017

Performance Improvement Project of Autologous Stem Cell Collection

Matthew R. Peterson; Michael B. Osswald; Michael Williams


Biology of Blood and Marrow Transplantation | 2017

Successful Pregnancy after Extensive Graft-Versus-Host Disease Following Matched-Related Donor Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome

Lauren E. Lee; Michael B. Osswald


Biology of Blood and Marrow Transplantation | 2016

Invasive Nocardiosis in Patients Intolerant to Trimethoprim/Sulfamethoxazole after Allogeneic Stem Cell Transplantation

Lauren E. Lee; Dana M. Blyth; Alice Barsoumian; Thomas Raj; Alexander W. Brown; Michael B. Osswald

Collaboration


Dive into the Michael B. Osswald's collaboration.

Top Co-Authors

Avatar

Alexander W. Brown

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lauren E. Lee

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alice Barsoumian

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

John S. Renshaw

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Matthew R. Peterson

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Michael A. Wiggins

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clinton K. Murray

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Dana M. Blyth

San Antonio Military Medical Center

View shared research outputs
Top Co-Authors

Avatar

Nikhil Huprikar

San Antonio Military Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge